PDF (2573K)
摘要
肺癌(lung cancer,LC)是全球高发的癌症类型,主要分为小细胞肺癌(small cell lung cancer,SCLC)和非小细胞肺癌(non-small cell lung cancer,NSCLC)。超过 50% 的 NSCLC 患者在初次诊断时已经发生转移,晚期治疗方案较为有限。免疫疗法的出现成为重要突破,其中 PD-1/PD-L1 抑制剂通过阻断 PD-1 与 PD-L1 的结合,恢复 T 细胞活性,从而抑制肿瘤的免疫逃逸。天然产物 PD-1/PD-L1 抑制剂(PD-1/PD-L1 inhibitors of natural product,PDNP)具有口服生物利用度好、组织渗透性强、成本低廉等优势,能够调节肿瘤微环境,增强免疫治疗的敏感性。本文综述了 PDNP 在治疗肺癌领域中的最新进展,主要包括:黄酮类、生物碱类、萜类以及其他类化合物,通过直接或间接的调控 PD-1/PD-L1 通路,激活 T 细胞从而抗肺癌作用机制,主要作用机制包括:直接阻断 PD-1/PD-L1 的结合;通过调节上游信号通路 Janus 激酶 2/信号转导子和转录激活子 3(Janus kinase 2/signal transducer and activator of transcription 3,JAK2/STAT3)、核因子 κB(nuclear factor kappa B,NF-κB)、磷脂酰肌醇 3-激酶/蛋白激酶 B/雷帕霉素靶蛋白(phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin,PI3K/AKT/mTOR)等;调节肿瘤微环境间接调控 PD-1/PD-L1 通路的激活状态。 本文通过总结多种中药及其有效成分在调节 PD-1/PD-L1 通路方面的作用,探讨其抗肺癌效果及协同减弱化疗药物耐药性的机制,旨在为肺癌治疗和逆转耐药提供新的思路,同时也为开发新型抗肺癌药物提供参考。
Abstract
Lung cancer (LC) is a globally prevalent type of cancer, mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 50% of NSCLC patients have developed metastasis at the initial diagnosis, resulting in limited treatment options for advanced stages. Immunotherapy has become the major breakthrough, among which PD-1/PD-L1 inhibitors block the binding between PD-1 and PD-L1, restore T cell activity, and inhibit tumor immune escape. Natural product-derived PD-1/PD-L1 inhibitors (PDNP) have the advantages of good oral bioavailability, strong tissue permeability, and low cost, and can regulate the tumor microenvironment and enhance the sensitivity of immunotherapy. This review summarizes the latest progress of PDNP in the treatment of LC, including flavonoids, alkaloids, terpenoids and other types of compounds. These compounds exert anti-lung cancer effects by directly or indirectly regulating the PD-1/PD-L1 pathway: directly blocking the binding of PD-1 and PD-L1; regulating upstream signaling pathways such as Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), nuclear factor kappa B (NF-κB), and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR); and indirectly regulating the activation state of the PD-1/PD-L1 pathway by modulating the tumor microenvironment. In addition, this review discusses the anti-lung cancer effects of various traditional Chinese medicines and their active ingredients in regulating the PD-1/PD-L1 pathway, as well as the mechanism of synergistically reducing chemotherapy drug resistance. It aims to provide new ideas for lung cancer treatment and reversing drug resistance, and also offer useful references for the development of new anti-lung cancer drugs.
关键词
Key words
[Author(id=1330571867832537524, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1370967149@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571867899646390, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571867832537524, language=EN, stringName=Siyuan ZHANG, firstName=Siyuan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571867949978039, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571867832537524, language=CN, stringName=张思源, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河南中医药大学 第三附属医院,郑州 450000,河南, bio={"content":"张思源,男,硕士,研究方向为中医药防治恶性肿瘤。E-mail:1370967149@qq.com
"}, bioImg=null, bioContent=张思源,男,硕士,研究方向为中医药防治恶性肿瘤。E-mail:1370967149@qq.com
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571867752845744, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, xref=null, ext=[AuthorCompanyExt(id=1330571867769622961, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China), AuthorCompanyExt(id=1330571867782205874, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河南中医药大学 第三附属医院,郑州 450000,河南)])]), Author(id=1330571868000309689, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571868063224251, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571868000309689, language=EN, stringName=Xiangqi WANG, firstName=Xiangqi, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571868113555900, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571868000309689, language=CN, stringName=王祥麒, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河南中医药大学 第三附属医院,郑州 450000,河南, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571867752845744, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, xref=null, ext=[AuthorCompanyExt(id=1330571867769622961, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China), AuthorCompanyExt(id=1330571867782205874, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河南中医药大学 第三附属医院,郑州 450000,河南)])]), Author(id=1330571868163887550, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=413672306@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330571868230996416, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571868163887550, language=EN, stringName=Yi YIN, firstName=Yi, middleName=null, lastName=YIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571868277133761, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, authorId=1330571868163887550, language=CN, stringName=尹怡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=河南中医药大学 第三附属医院,郑州 450000,河南, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571867752845744, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, xref=null, ext=[AuthorCompanyExt(id=1330571867769622961, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China), AuthorCompanyExt(id=1330571867782205874, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565357011211186, companyId=1330571867752845744, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=河南中医药大学 第三附属医院,郑州 450000,河南)])])]
张思源,王祥麒,尹怡.
中药及天然产物通过 PD-1/PD-L1 途径增强免疫疗法干预肺癌研究进展[J].
中国临床药理学与治疗学, 2026, 31(10): 1400-1409 DOI:10.12092/j.issn.1009-2501.2026.10.011
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [2] |
Eng L, Evans WK, Eisele M, et al. The international association for the study of lung cancer staging project: the impact of smoking status on lung cancer staging in the ninth edition of the TNM classification[J].J Thorac Oncol, 2025, 20(10): 1441-1458.
|
| [3] |
Wang B, Guo H, Xu H, et al. Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer[J].Cells, 2021, 10(10): 2620.
|
| [4] |
李松珍, 邵天航, 姚舒洋. 非小细胞肺癌寡转移的研究进展及挑战[J].中国肺癌杂志, 2025, 28(6): 467-471.
|
| [5] |
Pang K, Shi ZD, Wei LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade[J].Drug Resist Updat, 2022, 66: 100907.
|
| [6] |
Kluger H, Barrett JC, Gainor JF, et al. Society for immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors[J].J Immunother Cancer, 2023, 11(3): e005921.
|
| [7] |
Ri MH, Ma J, Jin X.Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer[J].J Ethnopharmacol, 2021, 281: 114370.
|
| [8] |
Li L, Pu H, Zhang X, et al. Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer[J].Crit Rev Oncol Hematol, 2025, 209: 104683.
|
| [9] |
Zhou Y, Chen C, Zhang X, et al. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J].J Immunother Cancer, 2018, 6(1): 155.
|
| [10] |
Li X, Yan S, Yang J, et al. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a network analysis of randomized controlled trials[J].Front Oncol, 2021, 10: 574752.
|
| [11] |
Gao P, Li X, Duan Z, et al. Improvement of the anti-cancer efficacy of PD-1/PD-L1 blockade: advances in molecular mechanisms and therapeutic strategies[J].MedComm (2020), 2025, 6(8): e70274.
|
| [12] |
Zhao Y, Harrison DL, Song Y, et al. Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells[J].Cell Rep, 2018, 24(2): 379-390.
|
| [13] |
Yu ZZ, Liu YY, Zhu W, et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers[J].J Immunother Cancer, 2023, 11(3): e006345.
|
| [14] |
Li K, Tian HQ.Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy[J].J Drug Target, 2018, 27(3): 244-256.
|
| [15] |
Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J].Front Immunol, 2022, 13: 964442.
|
| [16] |
Awad MM, Gadgeel SM, Borghaei H, et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC[J].J Thorac Oncol, 2020, 16(1): 162-168.
|
| [17] |
Renaud E, Ricordel C, Corre R, et al. Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)[J].Transl Lung Cancer Res, 2023, 12(2): 266-276.
|
| [18] |
Yao P, Liang S, Liu Z, et al. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer[J].Front Immunol, 2024, 15: 1343316.
|
| [19] |
Shen N, Wang TF, Gan Q, et al. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity[J].Food Chem, 2022, 383: 132531.
|
| [20] |
Zanoaga O, Braicu C, Jurj A, et al. Progress in research on the role of flavonoids in lung cancer[J].Int J Mol Sci, 2019, 20(17): 4291.
|
| [21] |
Sun Q, Liu Q, Zhou X, et al. Flavonoids regulate tumor-associated macrophages -From structure-activity relationship to clinical potential (Review)[J].Pharmacol Res, 2022, 184: 106419.
|
| [22] |
Kim JH, Kim YS, Choi JG, et al. Kaempferol and its glycoside, kaempferol 7-O-rhamnoside, inhibit PD-1/PD-L1 interaction in vitro[J].Int J Mol Sci, 2020, 21(9): 3239.
|
| [23] |
Jiang ZB, Wang WJ, Xu C, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer[J].Cancer Lett, 2021, 515: 36-48.
|
| [24] |
Zhang JL, Liu XQ, Zhang GY, et al. To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking[J].Front Pharmacol, 2023, 14: 1148171.
|
| [25] |
Li X, Bai Y, Zhou JW, et al. Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression[J].Eur J Pharmacol, 2025, 1004: 177984.
|
| [26] |
Jing L, Lin JR, Yang Y, et al. Quercetin inhibiting the PD-1/PD-L1 interaction for immune-enhancing cancer chemopreventive agent[J].Phytother Res, 2021, 35(11): 6441-6451.
|
| [27] |
Jasemi S, Khazaei H, Fakhri S, et al. Quercetin modulates the signalling pathways and therapeutic targets in the pathophysiology of lung cancer: a systematic review[J].Lett Drug Des Discov, 2024, 21(14): 2903-2915.
|
| [28] |
Yuan LW, Jiang XM, Xu YL, et al. Licochalcone a inhibits interferon-gamma- induced programmed death-ligand 1 in lung cancer cells[J].Phytomedicine, 2020, 80: 153394.
|
| [29] |
Rawangkan A, Wongsirisin P, Namiki K, et al. Green Tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth[J].Molecules, 2018, 23(8): 2071.
|
| [30] |
Cuyàs E, Pérez-Sánchez A, Micol V, et al. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer[J].Cell Cycle, 2016, 15(24): 3413-3418.
|
| [31] |
Bosch-Barrera J, Sais E, Teixidor-Vilà E, et al. The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report[J].Front Med (Lausanne), 2025, 12: 1612327.
|
| [32] |
Chen YC, He XL, Qi L, et al. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells[J].Biochem Pharmacol, 2022, 197: 114940.
|
| [33] |
Li J, Zhong XM, Zhao YS, et al. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo[J].Sci Rep, 2024, 14(1): 2348.
|
| [34] |
Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer[J].Annu Rev Physiol, 2019, 82: 103-126.
|
| [35] |
Mondal A, Gandhi A, Fimognari C, et al. Alkaloids for cancer prevention and therapy: Current progress and future perspectives[J].Eur J Pharmacol, 2019, 858: 172472.
|
| [36] |
Zhang S, Zhou L, Zhang M, et al. Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin[J].Front Pharmacol, 2020, 10: 1658.
|
| [37] |
Chen S, Ma S, Wang H, et al. Unraveling the mechanism of alkaloids from sophora alopecuroides linn combined with immune checkpoint blockade in the treatment of non-small cell lung cancer based on systems pharmacology[J].Bioorg Med Chem, 2022, 64: 116724.
|
| [38] |
Li L, Nong J, Li J, et al. Dendrobine suppresses tumor growth by regulating the PD-1/PD-L1 checkpoint pathway in lung cancer[J].Curr Cancer Drug Targets, 2025, 25(9): 1108-1117.
|
| [39] |
Jiang ZB, He QH, Kang LP, et al. Rutecarpine suppresses non-small cell lung cancer progression through activating the STING pathway and elevating CD8+T cells[J].Chem Biol Drug Des, 2025, 105(2): e70070.
|
| [40] |
Tan Y, Zhu QC, Yang ML, et al. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer[J].Pharmacol Res, 2024, 207: 107314.
|
| [41] |
Song Y, Jiang YX, Guan JY, et al. Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer[J].Acta Pharmacol Sin, 2025, 46(10): 2751-2764.
|
| [42] |
Zhu LL, Huang SS, Li JH, et al. Sophoridine inhibits lung cancer cell growth and enhances cisplatin sensitivity through activation of the p53 and Hippo signaling pathways[J].Gene, 2020, 742: 144556.
|
| [43] |
Guo WN, Zhou HF, Wang JB, et al. Aloperine suppresses cancer progression by interacting with VPS4A to inhibit autophagosome-lysosome fusion in NSCLC[J].Adv Sci (Weinh), 2024, 11(31): e2308307.
|
| [44] |
Luo L, Xu G.Fascaplysin induces apoptosis and ferroptosis, and enhances Anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) by promoting PD-L1 expression[J].Int J Mol Sci, 2022, 23(22): 13774.
|
| [45] |
Sun H, Zhang LJ, Sui BW, et al. The effect of terpenoid natural Chinese medicine molecular compound on lung cancer treatment[J].Evid Based Complement Alternat Med, 2021, 2021: 3730963.
|
| [46] |
Singh A, Debnath R, Sharma A, et al. Exploring the potential of terpenoids as a possible treatment for cancer: structure-activity relationship and mechanistic studies[J].Curr Med Chem, 2024, 31(24): 2799-2820.
|
| [47] |
Li M, Wang X, Wang Y, et al. Strategies for remodeling the tumor microenvironment using active ingredients of ginseng-a promising approach for cancer therapy[J].Front Pharmacol, 2021, 12: 797634.
|
| [48] |
Jiang ZS, Yang YF, Yang YL, et al. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune[J].Biomed Pharmacother, 2017, 96: 378-383.
|
| [49] |
Cao BX, Wei Q, Feng H, He Z.Mesoporous silica nano-modified Ginsenoside Rh2 promote tumor immunosuppression and inhibit lung cancer development through the PD-1/PD-L1 pathway[J].Ann Clin Lab Sci, 2024, 54(5): 597-603.
|
| [50] |
Hu ML, Yang J, Qu LL, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma[J].Food Funct, 2020, 11(1): 456-471.
|
| [51] |
Jin XY, Wuyun THS, Zhang Y, et al. Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems[J].J Nanobiotechnology, 2025, 23(1): 443.
|
| [52] |
Yang RJ, Pei TL, Huang RF, et al. Platycodon grandiflorum triggers antitumor immunity by restricting PD-1 expression of CD8+T cells in local tumor microenvironment[J].Front Pharmacol, 2022, 13: 774440.
|
| [53] |
Wang YH, Wang P, Liu JQ, et al. Panax notoginseng saponins enhance chemotherapy carboplatin and immune checkpoint blockades PD1ab by modulating SERPINE1 downregulation in LUAD[J].Pharmacogn Mag, 2025, 21(4): 1-11.
|
| [54] |
Wu T, Wu SK, Gao H, et al. Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment[J].Eur J Histochem, 2024, 68(4): 4098.
|
| [55] |
Chen YC, Huang MY, Zhang LL, et al. Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells[J].Chin J Nat Med, 2020, 18(7): 517-525.
|
| [56] |
Yang MM, Li ZY, Tao JP, et al. Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells[J].J Cancer Res Clin Oncol, 2021, 147(4): 1101-1113.
|
| [57] |
Khalil R, Green RJ, Sivakumar K, et al. Withaferin A increases the effectiveness of immune checkpoint blocker for the treatment of non-small cell lung cancer[J].Cancers (Basel), 2023, 15(12): 3089.
|
| [58] |
Jin GL, Ma M, Yang CY, et al. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway[J].Thorac Cancer, 2023, 14(24): 2493-2503.
|
| [59] |
Luo LX, Wu T, Ji MR, et al. Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer[J].Int Immunopharmacol, 2024, 133: 112098.
|
| [60] |
Lang LW, Liu XY, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth[J].PLos One, 2014, 9(6): e99584.
|
| [61] |
Zhang Y, Liu H, Wang L, et al. Natural-derived compounds reshape anti-tumor immunity to overcome PD-1/PD-L1 resistance in non-small-cell lung cancer[J].Phytomedicine, 2025, 132: 155871.
|
| [62] |
Li HF, Seeram NP, Liu C, et al. Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1[J].Front Oncol, 2022, 12: 995461.
|
| [63] |
Qu JJ, Mei QH, Liu L, et al. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer[J].Ther Adv Med Oncol, 2021, 13: 1758835921992968.
|
| [64] |
Xu MT, Lin XW, Xu HC, et al. Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1[J].J Clin Invest, 2026, 136(3): e197592.
|
| [65] |
Huang QY, Zang XL, Jin XU, et al. Discovery of PD-L1 peptide inhibitors from ascidian enzymatic hydrolysates by affinity ultrafiltration coupled to nanoLC-MS/MS[J].Mar Drugs, 2026, 23(1): 37.
|
| [66] |
Ahmed SF, Hossain MS, Mondal A, et al. In silico identification of promising PD-L1 inhibitors from selected Indian medicinal plants for treatment of triple negative breast cancer[J].Plos One, 2026, 11(3): e0327475.
|
| [67] |
Xia LL, Liu YY, Wang Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J].Oncologist, 2019, 24(suppl 1): S31-S41.
|
| [68] |
Chen L, Zheng Y, Zhou M, et al. Plant-derived bioactive molecules potentiate anti-PD-1 immunotherapy in lung cancer: molecular mechanisms and pre-clinical evidence[J].Int J Mol Sci, 2024, 25(20): 11023.
|
| [69] |
Kumar GS, Moustafa M, Sahoo AK, et al. Computational investigations on the natural small molecule as an inhibitor of programmed death ligand 1 for cancer immunotherapy[J].Life (Basel), 2022, 12(5): 659.
|
| [70] |
Bulbul EO, Okur NU. Difficulties in using natural herbal substances and their current use in some pharmaceutical dosage forms[J].Curr Pharm Des, 2025, 31(28): 2252-2266.
|
基金资助
国家中医优势专科建设项目(国中医药医政函〔2024〕90号)
河南省自然科学基金项目(252300420626)
河南省中医药研究重大专项课题(2022ZYZD13)